Mezagitamab
- Generic Name
- Mezagitamab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2227490-52-8
- Unique Ingredient Identifier
- 0XMR8L9LOL
- Background
Mezagitamab is under investigation in clinical trial NCT04278924 (Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Participants With Persistent/chronic Primary Immune Thrombocytopenia).
- Associated Conditions
- -
- Associated Therapies
- -
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of
Takeda's late-stage pipeline includes six programs with peak revenue potential of $10B - $20B, with Phase 3 data readouts expected in 2025 for Oveporexton, Zasocitinib, and Rusfertide. Regulatory filings for these drugs are planned for FY2025-2026, with additional filings anticipated through FY2029.
Earnings call: Takeda reports robust H1 growth, revises full-year guidance
Takeda Pharmaceutical reports 5% revenue growth in H1 FY24, driven by Growth & Launch portfolio, despite VYVANSE sales decline. The company raises full-year guidance, with core operating profit margin at 30.2%, and focuses on late-stage pipeline investments. Key highlights include ENTYVIO's double-digit growth and Phase 3 trials for TAK-861 and mezagitamab.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath